| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
52 |
| Employees |
55 |
| Revenues (TTM) (Millions $) |
58 |
| Net Income (TTM) (Millions $) |
-45 |
| Cash Flow (TTM) (Millions $) |
-41 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
G1 Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel targeted therapies for the treatment of cancer. The company specializes in developing small molecule inhibitors that selectively target specific proteins involved in cell cycle progression and DNA damage repair.
G1 Therapeutics aims to address the limitations of current cancer treatments by developing therapies that can improve outcomes for patients with a variety of cancer types. Their drug candidates are designed to target and modify the cell cycle, a critical process in the life cycle of a cell, to disrupt cancer cell growth and enhance the efficacy of existing cancer treatments.
The company's pipeline includes potential therapies for various solid tumors, including lung, breast, and pancreatic cancers. G1 Therapeutics focuses on both early-stage development to identify novel drug candidates and late-stage clinical trials to evaluate the safety and efficacy of these candidates.
Overall, G1 Therapeutics Inc is dedicated to advancing the field of oncology and providing innovative treatment options to cancer patients.
Company Address: 700 Park Offices Drive Research Triangle Park 27709 NC
Company Phone Number: 213-9835 Stock Exchange / Ticker: NASDAQ GTHX
|
%
